Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial

Authors

Hideto Ueki (ORCID: https://orcid.org/0000-0002-7742-4528)
Nobuyuki Hinata (ORCID: https://orcid.org/0000-0001-7014-6812)
Takuto Hara (ORCID: https://orcid.org/0000-0003-4524-2815)
Junya Furukawa (ORCID: https://orcid.org/0000-0001-8974-9218)
Toshiro Shirakawa (ORCID: https://orcid.org/0000-0003-3925-8730)
Yasumasa Kakei (ORCID: https://orcid.org/0000-0002-5997-514X)
Hideaki Miyake (ORCID: https://orcid.org/0000-0003-0563-4160)
Jun Teishima (ORCID: https://orcid.org/0000-0001-8429-1607)
Sae Murakami
Hiroshi Kita (ORCID: https://orcid.org/0000-0002-3158-2942)
Masato Fujisawa

Institutions

Hiroshima University (JP)
Kobe University Hospital (JP)
Kobe University (JP)
Tokushima University (JP)

Publication Details

Journal: BMC Cancer
Published: 2025-02-04
DOI: https://doi.org/10.1186/s12885-025-13514-4
Citations: 2
Primary Topic: Bladder and Urothelial Cancer Treatments
Type: article
Field-Weighted Citation Impact: 4.01

Funders

Japan Agency for Medical Research and Development

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial

Hideto Ueki, Nobuyuki Hinata, Takuto Hara, Junya Furukawa et al.

Feb 4, 2025

2 citations

BMC Cancer

Bladder and Urothelial Cancer Treatments

4.01

article

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial

Hideto Ueki, Nobuyuki Hinata, Takuto Hara, Junya Furukawa, Toshiro Shirakawa, Yasumasa Kakei, Hideaki Miyake, Jun Teishima, Sae Murakami, Hiroshi Kita, Masato Fujisawa

February 4, 2025article en

2 citations

Abstract

No abstract available for this paper.

BMC CancerVol. 25(1)

Hiroshima University (JP), Kobe University Hospital (JP), Kobe University (JP), Tokushima University (JP)

Japan Agency for Medical Research and Development

Good health and well-being

Openalex Percentile: Top 9%

Bladder and Urothelial Cancer Treatments

4.01

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety and efficacy of oral cancer vaccine B440 in patients with PD-1/PD-L1 inhibitor-resistant advanced urothelial cancer: a study protocol for a phase 1 multicenter, open-label, single-arm clinical trial — Hideto Ueki, Nobuyuki Hinata, et al. · BMC Cancer (2025) | TGRS Research Map | TGRS